Raise closed, search for fresh raises on Seedstage

Sparks Glencoe, MD

Revolutionizing endometriosis diagnosis with a non-invasive, AI-driven test offering accurate and rapid results.

• Innovative diagnostics: Offers a non-invasive, AI-driven test for endometriosis with 99%+ accuracy.
• Global distribution: Agreements in place for multiple international markets, including the UK and Canada.
• U.S. manufacturing: Fully developed and produced domestically, with regulatory submissions underway.
• Market opportunity: Targets a growing $2.91B endometriosis market projected by 2030.
• Post-treatment monitoring: Enables clinicians to track disease recurrence and treatment effectiveness.

ENDOSURE is revolutionizing the diagnosis of endometriosis with the development of its non-invasive, AI-driven ENDOSURE TEST, which provides highly accurate results within 30 minutes. Designed to detect all four stages of endometriosis, this innovative technology leverages a combination of the TRICORDER-3L device and proprietary consumable leads in a “razor and razorblade” model to empower clinicians with cost-effective and efficient diagnostic capabilities. By addressing the substantial global unmet need for accurate and less invasive endometriosis diagnosis, ENDOSURE, INC reduces the need for surgical procedures and improves post-treatment monitoring, providing critical tools for better patient care.

Fully developed and manufactured in the U.S., the ENDOSURE TEST is positioned for global reach with distribution agreements in key international markets, including the UK, Brazil, and Canada. The company has submitted CE MDR certification for European distribution and is targeting FDA approval in the U.S. by Q2 2025. With strong patent protection and a commitment to advancing women’s healthcare, ENDOSURE, INC is leveraging its innovative diagnostic solution to transform outcomes for over 190 million women affected by endometriosis worldwide, while establishing itself as a leader in this growing market.

Company Info

ENDOSURE develops a non-invasive, AI-driven diagnostic tool for accurate and rapid detection of endometriosis.

ENDOSURE, INC has developed the ENDOSURE TEST, a non-invasive, 30-minute, AI-driven diagnostic tool designed to detect endometriosis across all four stages with over 99% accuracy. The technology incorporates the TRICORDER-3L device and proprietary EKG-type consumable leads, offering an accessible and cost-effective alternative to invasive diagnostic methods. Fully developed in the U.S., the ENDOSURE TEST is ready for distribution in markets such as the UK, Brazil, Gulf States, Israel, and Canada, with CE MDR certification expected by Q4 2024 and FDA approval submission targeting Q2 2025.

Addressing a significant unmet medical need, ENDOSURE, INC provides an innovative solution to the global challenge of delayed and inadequate endometriosis diagnosis. The test also offers post-treatment monitoring capabilities to assess treatment efficacy and detect recurrence. With strong patent protection and a scalable business model, ENDOSURE is poised to transform endometriosis care while addressing the growing demand in the $2.91 billion global market projected for 2030.